Compare SRL & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRL | ADAG |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | China | China |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.5M | 254.4M |
| IPO Year | 1996 | 2020 |
| Metric | SRL | ADAG |
|---|---|---|
| Price | $6.13 | $3.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 12.8K | ★ 95.1K |
| Earning Date | 05-12-2026 | 04-01-2026 |
| Dividend Yield | ★ 16.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.13 | $1.44 |
| 52 Week High | $10.39 | $4.75 |
| Indicator | SRL | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 28.74 | 50.91 |
| Support Level | $5.37 | $3.35 |
| Resistance Level | $6.44 | $3.99 |
| Average True Range (ATR) | 0.35 | 0.32 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 48.57 | 66.46 |
Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.